Search Results

Study Presented at CIRSE Explores Ocular Radiation Exposure and Role of Protective Eyewear

September 22, 2017—Gerard Goh, MBBS, FRANZCR, EBIR, and colleagues presented data at CIRSE 2017, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe held September 16–20 in Copenhagen, Denmark, that showed many physicians and staff performing interventional procedures could exceed recommended ocular radiation dose limits if not wearing protective glasses.

Initial Procedure Conducted With Hansen Medical's 10-F Robotic Catheter

May 14, 2015—Hansen Medical, Inc. announced the completion of the first clinical procedure with the Magellan 10-F robotic catheter, which recently received European CE Mark approval for use in the peripheral vasculature.

Pivotal Trial Begins for Instylla’s Embrace Hydrogel Embolic System to Treat Hypervascular Tumors

March 30, 2021—Instylla, Inc. announced the enrollment of the first patients in the pivotal Embrace Hydrogel Embolic System (HES) global randomized clinical trial for the treatment of hypervascular tumors.

CUC and Dr. Yuji Okuno Partner to Expand to Musculoskeletal Embolotherapy in the United States

November 12, 2025—CUC Inc., a provider of health care management and operational support services headquartered in Tokyo, Japan, announced it has signed a Memorandum of Understanding (MOU) with Yuji Okuno, MD, to form a strategic partnership for the expansion of chronic pain treatment business in the United States.

Medinol’s ChampioNIR Peripheral DES Implanted in FIH Procedure

October 7, 2024—Medinol Ltd. announced the first-in-human (FIH) implantation of the ChampioNIR drug-eluting peripheral stent.

Instylla’s Embrace Hydrogel Embolic System Evaluated in First-In-Human Trial

March 15, 2022—Instylla, Inc., a developer of liquid embolics for peripheral vascular embolotherapy, announced that results from the first-in-human clinical trial of the company’s Embrace hydrogel embolic system (HES) for the treatment of hypervascular tumors were published by Gerard S. Goh, MBBS, et al online ahead of print in the Journal of Vascular and Interventional Radiology.

Instylla’s Embrace Hydrogel Embolic System Evaluated in Preclinical Hemorrhage Models

July 26, 2022—Instylla, Inc., a developer of liquid embolics for peripheral vascular embolotherapy, announced two publications of studies that evaluated the company’s Embrace hydrogel embolic system (HES) in preclinical porcine hemorrhage models.